Overview

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal Impairment

Status:
COMPLETED

Trial end date:
2024-12-23

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of AZD5462 in participants with impaired renal function.

Phase:

PHASE1

Details

Lead Sponsor:

AstraZeneca